Celldex Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 12, 2019 and accepted by EDGAR at Nov 12, 2019, 09:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $546.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $2.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $11.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $32.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$11.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$42.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$11.4m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$40.4m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | −$0.75 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | −$2.92 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$35.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $626.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-09-30 | $16.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $75.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $131.8m | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $11.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $30.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | $101.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-19-062181. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.